Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
Jonah Feldman
Advertisement
Articles by Jonah Feldman
A prespecified interim analysis from the phase 3 TRANSFORM study showed an event-free survival benefit with the second-line therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
3
Guess the Therapy Answer October 16, 2025
4
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
5
